Histiocytic neoplasms, version 2.2021

Ronald S. Go; Eric Jacobsen; Robert Baiocchi; Ilia Buhtoiarov; Erin B. Butler; Patrick K. Campbell; Don W. Coulter; Eli Diamond; Aron Flagg; Aaron M. Goodman; Gaurav Goyal; Dita Gratzinger; Paul C. Hendrie; Meghan Higman; Michael D. Hogarty; Filip Janku; Reem Karmali; David Morgan; Anne C. Raldow; Alexandra Stefanovic; Srinivas K. Tantravahi; Kelly Walkovich; Ling Zhang; Mary Anne Bergman; Susan D. Darlow

doi:10.6004/jnccn.2021.0053

Histiocytic neoplasms, version 2.2021

Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra StefanovicSrinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, Susan D. Darlow

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Original language	English (US)
Pages (from-to)	1277-1303
Number of pages	27
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2021.0053
State	Published - Nov 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2021.0053

Cite this

Go, R. S., Jacobsen, E., Baiocchi, R., Buhtoiarov, I., Butler, E. B., Campbell, P. K., Coulter, D. W., Diamond, E., Flagg, A., Goodman, A. M., Goyal, G., Gratzinger, D., Hendrie, P. C., Higman, M., Hogarty, M. D., Janku, F., Karmali, R., Morgan, D., Raldow, A. C., ... Darlow, S. D. (2021). Histiocytic neoplasms, version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 19(11), 1277-1303. https://doi.org/10.6004/jnccn.2021.0053

Go, RS, Jacobsen, E, Baiocchi, R, Buhtoiarov, I, Butler, EB, Campbell, PK, Coulter, DW, Diamond, E, Flagg, A, Goodman, AM, Goyal, G, Gratzinger, D, Hendrie, PC, Higman, M, Hogarty, MD, Janku, F, Karmali, R, Morgan, D, Raldow, AC, Stefanovic, A, Tantravahi, SK, Walkovich, K, Zhang, L, Bergman, MA & Darlow, SD 2021, 'Histiocytic neoplasms, version 2.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 11, pp. 1277-1303. https://doi.org/10.6004/jnccn.2021.0053

@article{4810fbb8603245d8a4a590d0f7b75576,

title = "Histiocytic neoplasms, version 2.2021",

abstract = "Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.",

author = "Go, {Ronald S.} and Eric Jacobsen and Robert Baiocchi and Ilia Buhtoiarov and Butler, {Erin B.} and Campbell, {Patrick K.} and Coulter, {Don W.} and Eli Diamond and Aron Flagg and Goodman, {Aaron M.} and Gaurav Goyal and Dita Gratzinger and Hendrie, {Paul C.} and Meghan Higman and Hogarty, {Michael D.} and Filip Janku and Reem Karmali and David Morgan and Raldow, {Anne C.} and Alexandra Stefanovic and Tantravahi, {Srinivas K.} and Kelly Walkovich and Ling Zhang and Bergman, {Mary Anne} and Darlow, {Susan D.}",

year = "2021",

month = nov,

doi = "10.6004/jnccn.2021.0053",

language = "English (US)",

volume = "19",

pages = "1277--1303",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - Histiocytic neoplasms, version 2.2021

AU - Go, Ronald S.

AU - Jacobsen, Eric

AU - Baiocchi, Robert

AU - Buhtoiarov, Ilia

AU - Butler, Erin B.

AU - Campbell, Patrick K.

AU - Coulter, Don W.

AU - Diamond, Eli

AU - Flagg, Aron

AU - Goodman, Aaron M.

AU - Goyal, Gaurav

AU - Gratzinger, Dita

AU - Hendrie, Paul C.

AU - Higman, Meghan

AU - Hogarty, Michael D.

AU - Janku, Filip

AU - Karmali, Reem

AU - Morgan, David

AU - Raldow, Anne C.

AU - Stefanovic, Alexandra

AU - Tantravahi, Srinivas K.

AU - Walkovich, Kelly

AU - Zhang, Ling

AU - Bergman, Mary Anne

AU - Darlow, Susan D.

PY - 2021/11

Y1 - 2021/11

N2 - Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

AB - Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

UR - http://www.scopus.com/inward/record.url?scp=85120073011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120073011&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0053

DO - 10.6004/jnccn.2021.0053

M3 - Article

C2 - 34781268

AN - SCOPUS:85120073011

SN - 1540-1405

VL - 19

SP - 1277

EP - 1303

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

Histiocytic neoplasms, version 2.2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this